Pune, India, 2022, MRFR Press Release/- Market Research Future has published a Cooked Research Report on the Global New-Born Screening Market.
The New-Born Screening Market is projected to reach USD 876.61 Million by 2030 at 8.20% CAGR during the forecast period 2022-2030. Newborn screening is the practice of testing every newborn for some harmful or possibly fatal disorders that are not otherwise obvious at birth. New-born screening involves the use of various devices for the screening procedure. Diseases such as phenylketonuria, congenital hypothyroidism, galactosemia, sickle cell disease, cystic fibrosis, tyrosinemia, and other such disorders can be screened using new-born screening devices. The rising prevalence of neonatal conditions and government support along with new-born screening programs have led to the growth of the new-born screening market in recent years. Additionally, increasing neonatal population and technological advancements are likely to contribute to the growth of the market over the assessment period.
The key factors driving the market growth are increasing spending by government organizations on healthcare, rising prevalence of diseases in new-born children, and increasing neonatal population. However, factors such as the unreliability of new-born screening tests and lack of proper healthcare infrastructure and trained professionals may hamper the market growth.
The global new-born screening market is segmented into product, technology, test type, and end-user
The global new-born screening market by-products has been bifurcated into instruments and reagents and assay kits. By technology, the new-born screening market has been divided into tandem mass spectrometry, DNA assays, electrophoresis, pulse oximetry, immunoassays, and enzymatic assays, and hearing screening technology. Based on the test type, it has been segregated into dry blood spot tests, critical congenital heart disease (CCHD) tests, urine tests, and hearing screening tests. The global new-born screening market, by end-user, has been classified as hospitals, maternity and specialty clinics, diagnostic centers, and others.
Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of New-Born Screening Market Research Report
The global new-born screening market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas are anticipated to hold a significant share in the global new-born screening market. According to data published by the Centers for Disease Control and Prevention (CDC) in November 2018, congenital heart defects (CHD) affect approximately 1% or about 40,000 births per year in the US. Also, increasing awareness and rising demand for new-born screening are expected to drive market growth.
The new-born screening market in Europe is expected to propel owing to factors such as the rising prevalence of neonatal disorders and raising awareness about these disorders and their screening programs. According to a report published by the European Medicines Agency in May 2015, 1 in 10,000 babies born in the European Union was affected by perinatal asphyxia (a neonatal disorder wherein babies are born without enough oxygen in the blood). Also, technological advancements in the industry and government support in terms of National Health Service and health insurance are expected to drive market growth.
Asia-Pacific is anticipated to be the fastest-growing region in the global new-born screening market owing to the rising neonatal population, increasing mortality rate of neonates, and improving healthcare infrastructure. According to data published by the United Nation’s International Children’s Emergency Fund (UNICEF), the rate of neonatal mortality in India was 24% in 2017. According to a report published by the National Center for Biotechnology Information (NCBI) in December 2016, approximately 0.75 million neonates die in India every year. The neonatal mortality rate (NMR) for India is the highest for any country in the world. Also, the rising prevalence of neonatal disorders in developing countries and government support is fueling the growth in the market.
The new-born screening market in the Middle East & Africa is expected to significantly grow owing to the developing healthcare infrastructure and government support. The American Society of Hematology (ASH), led a campaign to fight the sickle cell disease in Africa in June 2018. It also urged the governments, particularly in Sub-Saharan Africa, to invest in new-born screening of the disease. Additionally, raising awareness of newborn screening is fueling the growth in the market.
MRFR recognizes the following companies as the Key Players in the Global New-Born Screening Market—SCIEX (US), PerkinElmer Inc. (US), WATERS (US), Natus Medical Incorporated (US), Masimo Corporation (US), Agilent Technologies Inc. (US), Bio-Rad Laboratories, Inc. (US), Medtronic (Ireland), GENERAL ELECTRIC (Boston), Trivitron Healthcare (India), and ZenTech SA (Belgium)
Key Findings of the Study
The New-Born Screening Market is projected to reach USD 876.61 Million by 2030 at 8.20% CAGR during the forecast period 2022-2030.